Nupathe (Jane Hollingsworth, CEO) raises $30M in Series B with Quaker BioVentures and S.R. One as Leads

From: CityBizList Philadelphia
Read entire press release

"The Series B financing represents a significant milestone for NuPathe and comes at an exciting time for our company," said Jane Hollingsworth, chief executive officer and co-founder of NuPathe Inc. "NuPathe is now in a position to optimize the development and commercialization of NP101, a unique treatment for acute migraine, as well as NP201, a novel product for Parkinson's disease. We are grateful to have such highly regarded investors guiding our growth and providing the support we need to advance the treatment of some of the most devastating neurological and psychiatric diseases."

...

"We are impressed with the leadership and focus of Jane and her management team, particularly with the progress they have made in the development of the lead product and pipeline," said Michael C. Diem, M.D., principal at SR One Ltd.